Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL).
G
G
Garcia-Manero
H M
HM
Kantarjian
S
S
Kornblau
E
E
Estey
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000628:therapy; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000473:pathology; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D014212:Tretinoin / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D014212:Tretinoin; D014750:Vincristine; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate